Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2024-03-12 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
关于收到四川证监局责令改正措施的决定及警示函的公告
Legal Proceedings Report Classification · 95% confidence The document is an official announcement from a company regarding regulatory actions taken by the Sichuan Securities Regulatory Bureau. It details administrative regulatory measures and warning letters issued due to internal control and accounting issues. The document does not contain financial statements or detailed financial data but rather describes regulatory sanctions and the company's response. It is a regulatory announcement about legal and compliance matters, not a financial report or earnings release. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is short and focused on regulatory measures, not a full audit or annual report.
2024-03-12 Chinese
关于设立合资公司的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of establishing a joint venture company, including details about the investment, registration, and share pledge agreements. It does not contain financial statements, earnings data, or detailed financial analysis. The document length is about 2300 characters, which is relatively short and primarily serves as a formal announcement of corporate actions and agreements. It fits the category of a regulatory announcement about corporate developments rather than a full financial report or detailed management discussion. Therefore, it is best classified as a Regulatory Filing (RNS).
2024-03-06 Chinese
关于持股 5%以上股东减持计划实施期限届满暨未减持的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the expiration of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details that the shareholder did not reduce their holdings during the planned period and provides specifics about the shareholding before and after the plan. The document references compliance with relevant securities laws and regulations but does not contain financial statements or detailed financial analysis. It is a regulatory announcement about shareholding changes and compliance, not a financial report or earnings release. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, confirming this classification.
2024-02-26 Chinese
北京市金杜律师事务所关于成都市贝瑞和康基因技术股份有限公司2024年第一次临时股东大会之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, and voting procedures of the 2024 first extraordinary general meeting (临时股东大会) of Chengdu Berry Genomics Co., Ltd. It details the legal compliance of the meeting's procedures, attendees' qualifications, and voting results. The document does not contain financial statements or management discussion but focuses on the legality and validity of the shareholder meeting and its resolutions. It is not a full annual or interim report, nor an earnings release or investor presentation. It is also not a proxy solicitation or voting results announcement by itself, but a legal opinion on the meeting. Given the nature of the document as a legal opinion related to a shareholder meeting, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or compliance documents that do not fit other categories.
2024-02-21 Chinese
2024年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the 2024 first extraordinary shareholders meeting of the company. It details the meeting time, voting methods, attendance, and the voting results on specific proposals. It also includes legal opinions confirming the validity of the meeting and voting process. There are no financial statements or detailed financial data presented, nor is this a full report or presentation. The document is an official announcement of the voting results from a shareholders meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1996 characters), and it contains detailed voting results rather than just a notice of a report publication or a regulatory filing. Therefore, the classification is DVA with high confidence.
2024-02-21 Chinese
关于控股股东进行股票质押式回购交易补充质押的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding the supplementary pledge of shares by the controlling shareholder of the company. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company capital, and clarifies that the pledge does not involve new financing or affect company control. The document is short (1661 characters) and focuses on share pledge transactions by a major shareholder, which fits the category of Transaction in Own Shares (POS). It is not a financial report, earnings release, or regulatory certification, nor is it an announcement of a report publication. Therefore, the appropriate classification is POS.
2024-02-07 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.